Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Ines Godet
 + 1757 word(s) 1757 2022-02-22 05:08:42 |
2 format corrected.
Beatrix Zheng
 -5 word(s) 1752 2022-03-01 02:46:54 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Godet, I. Detection of Hypoxia in Cancer Models. Encyclopedia. Available online: https://encyclopedia.pub/entry/20006 (accessed on 06 July 2024).
Godet I. Detection of Hypoxia in Cancer Models. Encyclopedia. Available at: https://encyclopedia.pub/entry/20006. Accessed July 06, 2024.
Godet, Ines. "Detection of Hypoxia in Cancer Models" Encyclopedia, https://encyclopedia.pub/entry/20006 (accessed July 06, 2024).
Godet, I. (2022, February 28). Detection of Hypoxia in Cancer Models. In Encyclopedia. https://encyclopedia.pub/entry/20006
Godet, Ines. "Detection of Hypoxia in Cancer Models." Encyclopedia. Web. 28 February, 2022.
Detection of Hypoxia in Cancer Models
Edit
This entry is adapted from the peer-reviewed paper 10.3390/cells11040686

The rapid proliferation of cancer cells combined with deficient vessels cause regions of nutrient and O2 deprivation in solid tumors. Some cancer cells can adapt to these extreme hypoxic conditions and persist to promote cancer progression. Intratumoral hypoxia has been consistently associated with a worse patient prognosis. In vitro, 3D models of spheroids or organoids can recapitulate spontaneous O2 gradients in solid tumors. Likewise, in vivo murine models of cancer reproduce the physiological levels of hypoxia that have been measured in human tumors. Given the potential clinical importance of hypoxia in cancer progression, there is an increasing need to design methods to measure O2 concentrations. O2 levels can be directly measured with needle-type probes, both optical and electrochemical. Alternatively, indirect, noninvasive approaches have been optimized, and include immunolabeling endogenous or exogenous markers. Fluorescent, phosphorescent, and luminescent reporters have also been employed experimentally to provide dynamic measurements of O2 in live cells or tumors. In medical imaging, modalities such as MRI and PET are often the method of choice. 

hypoxia detection cancer HIF

1. Introduction

Regions of hypoxia arise in 90% of solid tumors as cancer cells quickly proliferate, and scarce, newly formed vasculature fails to supply sufficient oxygen [1]. In patients with breast cancer, the mean partial pressure of oxygen (PO2) in breast tumors ranges from 2.5 to 28 mmHg, with a median value of 10 mmHg (1% O2), while normal human breast tissue has a median value of 65 mmHg (8% O2) [2]. Several studies have demonstrated that patients with hypoxic tumors have an increased risk of metastasis and mortality [3][4][5]. Hypoxia has been reported to be an adverse prognostic indicator, independent of clinical stage, at the time of diagnosis [6]. Cancer cells can adapt and survive under oxygen deprivation, and the most well-reported mechanism involves the hypoxia-inducible factors (HIFs) [7]. In an O2-rich environment, prolyl hydroxylases (PHDs) hydroxylate HIF-1α and HIF-2α. The von Hippel–Lindau (VHL) E3 ubiquitin ligase ubiquitinates hydroxylated HIF-1α and HIF-2α causing its proteasomal degradation [8]. In contrast, under hypoxia, HIF-1α and HIF-2α subunits become stabilized and bind to the HIF-1β subunit [9]. Both HIF-1 and HIF-2 heterodimers recognize and bind to the 5′-ACGTG-3′ enhancer sequence, resulting in the transcriptional regulation of more than a thousand genes [10][11]. The abundance and activity of both HIF-1α and HIF-2α can also be enhanced due to post-translational modifications [12]. HIF-regulated genes have been associated with angiogenesis, apoptosis, cell proliferation, cell survival, metabolism, invasion, metastasis, altered pH, and chemoresistance [5].
Hypoxia has been detected using both direct and indirect methods in cells cultured in the laboratory and animal and human tumors. Direct O2 measurements have been made in solid tumors of cancer patients using needle-type O2 electrodes [2][13][14][15]. Indirect methods, such as the immunolabeling of HIF-1/2α or downstream HIF-targets, have been used to detect potential regions of hypoxia in fixed tissue after surgical resection or biopsy [16]. Moreover, exogenous 2-nitroimidazole probes, such as pimonidazole, can be delivered to animals or humans and incorporate into hypoxic adducts that can be immunolabeled once the tissue is harvested and fixed [17]. Immunolabeling-based methods are insightful but limited by protein turnover and fixation artifacts, and they cannot be used for real-time assessment. For preclinical studies, several groups have used DNA constructs that cause the cell to express reporters, such as fluorescent proteins or luciferase, in a HIF-dependent manner as an indirect real-time readout of hypoxia [18][19]. In preclinical and clinical approaches, intratumoral O2 levels are measured in real-time, albeit indirectly, using techniques such as Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) [5].

2. Current Insights

Intratumoral hypoxia has a frequent incidence in solid primary tumors and greatly contributes to tumorigenesis and metastasis. In the early 1990s, multiple studies investigated the O2 levels in solid tumors utilizing polarographic probes, such as Clark probes, that are now commercially available from companies such as Eppendorf. They established that intratumoral hypoxia is an adverse indicator for patients with cancer [5]. Since then, in vitro models that progressed from 2D monolayer cell culture to 3D cellular clusters have been used to model physiological O2 and nutrient gradients found in vivo. In vivo models faithfully reproduce the lack of vasculature and subsequent hypoxic regions in solid tumors. Although mouse models are a standard in cancer research, larger animals, such as rats [20] or rabbits [21], better resemble human scale and physiology and have been used to test O2 detection methods. Furthermore, non-human primate models have been employed to assess biosafety parameters such as the biodistribution of radioactive hypoxia tracers for PET imaging [22] or to determine the effect of BOLD signal on neural activity [23]. As the relevance of intratumoral hypoxia increased, methods to assess O2 levels both in vitro and in vivo became critical.
The selection of adequate methods to monitor O2 levels in experimental set-ups must take several factors into account, namely whether they can be performed in live animals or cells versus fixed tissues and the scale and sensitivity of the measurement. To facilitate comparison across the different methods described here, the techniques were categorized according to a series of features that the researchers consider relevant and their applicability in different experimental settings (Table 1). A method can be selected to fit the scientific question or the available resources.
Table 1. Compilation of methods to detect hypoxia. Partially adapted from [24][25]. Y = Yes; N = No; NA = Not Applicable; +/− = positive-negative readout. LM = Light Microscopy; FM = Fluorescent Microscopy; FC = Flow Cytometry; Temp = Temporal; Res = Resolution; Non-Inv = non-invasive.
Method Detection Live Direct Readout Scale Single Cell Res Non
-Inv		 Dyna-mic Temp.
Res		 In
Vitro		 Animal Human Processing
Endogenous markers LM, FM, FC N N +/− μm [26] Y NA N NA Y Y Y Fixation
Staining
Exogenous markers LM, FM, FC N N +/− μm [27] Y NA N NA Y Y Y Fixation
Staining
Fluorescent Reporter FM, FC, Fluorescent imager Y N +/− [24] μm [24] Y Y Y ms [24] Y Y N Fixation
Dissociation
NTR-sensitive
Fluorescence		 FM, FC, Fluorescent imager Y N +/− [24] μm [28] Y Y Y ms [24] Y Y N Fixation
Dissociation
Phosphorescence
CELI		 FM, Fluorescent imager Y Y pO2 [24] μm [24] N Y Y s [25] Y Y N Pre-exposure
PAI Ultrasound Y N sO2 [24] μm [24][29] N Y Y ms [24] Y Y N Pre-injection
BLI Luminescent
imager		 Y N Intensity Gradient [30] mm [31] N Y Y min [29] Y Y N Pre-injection
MRI MRI machine Y N B: deoxyHb [32]
T: [O2(s)] [32]		 mm [33] N Y Y s-min [25] N Y Y Pre-injection
EPRI EPRI machine
Spin tracers		 Y Y pO2 [34] mm [29][33] N Y Y min-hr [25][29] N Y N Pre-injection
PET Radiolabeled Tracers Y N radiotracer [29] mm [33][35] N Y Y min-hr [36] N Y Y Pre-injection
Clark
Electrode		 Current meter Y Y pO2 [37] μm [37] N N Y s [37] N Y Y Implant/
Insertion
Invasive
optical probes		 Optical
Detector		 Y Y pO2 [37] μm [37] N N Y ms [37] Y Y Y Insertion
While O2-electrode or optical probes provide an accurate readout in situ, alternative methods have been established to overcome the need for an invasive approach to assess deeper tumors and preserve tissue integrity. Immunolabeling of hypoxia-regulated proteins in tissue sections has been extensively optimized to be performed in vitro and has also been employed in the clinic by staining human pathological specimens [38][39]. This particular approach is limited by rapid protein turnover and potential cross-regulation of these target proteins via mechanisms other than hypoxia. Another multifaceted approach requires the delivery of 2-nitroimidazole probes such as pimonidazole, which can be detected exclusively in hypoxic cells by immunolabeling. This method can be applied to basic cell culture or animal and human tissue sections [40]. However, immunolabeling techniques can only allow imaging of hypoxic regions when the tissue is resected and processed. Moreover, the staining is usually performed in a small portion of harvested and fixed tissue, which might not represent the entire tumor, particularly in the case of a human biopsy.
Phosphorescent and nitroreductase-regulated fluorescent probes are an easy-to-implement alternative to investigate dynamic changes in hypoxia. These probes can be added to cell culture medium or delivered to the animal intravenously to be immediately measured. This feature makes them readily marketable, and several options are available commercially. Basic scientists have taken advantage of transcriptionally regulated fluorescent, and luminescent reporters to monitor the dynamics of hypoxic and reoxygenated cancer cells. These approaches require extensive design and optimization, which can be time-consuming. However, fluorescent markers have allowed us to isolate hypoxic and reoxygenated cells to begin to unravel their contribution to tumor progression and metastatic spread.
Recent advances in medical imaging have optimized imaging modalities such as MRI and PET to specifically detect O2 levels in a tumor. Basic scientists have kept up with these advances by utilizing these methods in preclinical models. Furthermore, in murine models, whole-body imaging has been extensively employed by utilizing BLI and PAI to enable time course studies in live animals. Although whole-body imaging allows dynamic monitoring of intratumoral hypoxia throughout long time-course experiments and better resembles clinical methods, the low spatial resolution prevents single-cell tracing.
Recently, promising efforts have been made to improve O2 resolution and measure actual PO2 levels using PET. Furthermore, both CELI and EPRI are high O2-resolution (PO2) emerging technologies with clinical potential that are currently being optimized to obtain FDA approval. In summary, whole-body imaging methods allow dynamic monitoring of O2 levels in mice and are the most promising path for clinical use, but lower spatial and oxygen resolution or access to specialized high-cost equipment are limiting factors in preclinical research. Currently, PET offers the safest and cost-efficient option to be implemented in the clinic.
Hypoxia is a condition studied across multiple research fields, particularly in the context of developmental biology with focus on embryogenesis [41]. Aside from cancer, hypoxia also plays pathophysiological roles in myocardial ischemia, metabolic diseases, chronic heart and kidney diseases, and in reproductive disorders [42]. Although significant efforts have been conducted to detect and monitor hypoxic O2 levels experimentally, it is still challenging. Many of the described methods are only a proxy for actual levels of O2, can be challenging to adapt, or require access to specialized equipment. However, current techniques have been critical in establishing findings that have impacted the field of cancer research, namely: (1) the prognostic value of intratumoral hypoxia; (2) the hypoxic-upregulation of cancer hallmarks such as metabolism, migration, and chemoresistance; and (3) the significant contribution of cells that experienced intratumoral hypoxia to metastasis. As the role of hypoxia in cancer progression and resistance becomes more defined, multiple therapeutic approaches are being investigated pre-clinically and in clinical trials [43][44]. Thus, there is an urgent need to standardize methods to detect intratumoral hypoxia to (1) aid treatment decision and (2) assess whether hypoxia-targeted therapies perform as designed. The results here could aid researchers in selecting a suitable method to detect hypoxia in their studies by providing a side-by-side comparison across the most well-established and most recently optimized methods.

References

  1. Cosse, J.-P. Tumour Hypoxia Affects the Responsiveness of Cancer Cells to Chemotherapy and Promotes Cancer Progression. Anti-Cancer Agents Med. Chem. 2008, 8, 790–797.
  2. Vaupel, P.; Höckel, M.; Mayer, A. Detection and Characterization of Tumor Hypoxia Using pO2 Histography. Antioxid. Redox Signal 2007, 9, 1221–1236.
  3. Vaupel, P.; Mayer, A.; Briest, S.; Höckel, M. Oxygenation gain factor: A novel parameter characterizing the association between hemoglobin level and the oxygenation status of breast cancers. Cancer Res. 2003, 63, 7634–7637.
  4. Vaupel, P.; Mayer, A. Hypoxia in cancer: Significance and impact on clinical outcome. Cancer Metastasis Rev. 2007, 26, 225–239.
  5. Walsh, J.C.; Lebedev, A.; Aten, E.; Madsen, K.; Marciano, L.; Kolb, H.C. The Clinical Importance of Assessing Tumor Hypoxia: Relationship of Tumor Hypoxia to Prognosis and Therapeutic Opportunities. Antioxid. Redox Signal. 2014, 21, 1516–1554.
  6. Vaupel, P.; Mayer, A.; Höckel, M. Tumor Hypoxia and Malignant Progression. Methods Enzymol. 2004, 381, 335–354.
  7. Dengler, V.L.; Galbraith, M.; Espinosa, J.M. Transcriptional regulation by hypoxia inducible factors. Crit. Rev. Biochem. Mol. Biol. 2014, 49, 1–15.
  8. Kaelin, W.G., Jr.; Ratcliffe, P.J. Oxygen Sensing by Metazoans: The Central Role of the HIF Hydroxylase Pathway. Mol. Cell 2008, 30, 393–402.
  9. Jiang, B.-H.; Rue, E.; Wang, G.L.; Roe, R.; Semenza, G.L. Dimerization, DNA Binding, and Transactivation Properties of Hypoxia-inducible Factor 1. J. Biol. Chem. 1996, 271, 17771–17778.
  10. Wang, G.L.; Semenza, G.L. Purification and Characterization of Hypoxia-inducible Factor. J. Biol. Chem. 1995, 270, 1230–1237.
  11. Ye, I.C.; Fertig, E.J.; Digiacomo, J.W.; Considine, M.; Godet, I.; Gilkes, D.M. Molecular Portrait of Hypoxia in Breast Cancer: A Prognostic Signature and Novel HIF-Regulated Genes. Mol. Cancer Res. 2018, 16, 1889–1901.
  12. Daly, L.A.; Brownridge, P.J.; Batie, M.; Rocha, S.; Sée, V.; Eyers, C.E. Oxygen-dependent changes in binding partners and post-translational modifications regulate the abundance and activity of HIF-1α/2α. Sci. Signal. 2021, 14, 6685.
  13. Höckel, M.; Knoop, C.; Schlenger, K.; Vorndran, B.; Bauβnann, E.; Mitze, M.; Knapstein, P.G.; Vaupel, P. Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother. Oncol. 1993, 26, 45–50.
  14. Hopf, H.W.; Hunt, T.K. Comparison of Clark Electrode and Optode for Measurement of Tissue Oxygen Tension. Adv. Exp. Med. Biol. 1994, 345, 841–847.
  15. Nordsmark, M.; Bentzen, S.M.; Overgaard, J. Measurement of Human Tumour Oxygenation Status by a Polarographic Needle Electrode: An analysis of inter- and intratumour heterogeneity. Acta Oncol. 1994, 33, 383–389.
  16. Ambrosetti, D.; Dufies, M.; Dadone, B.; Durand, M.; Borchiellini, D.; Amiel, J.; Pouyssegur, J.; Rioux-Leclercq, N.; Pages, G.; Burel-Vandenbos, F.; et al. The two glycolytic markers GLUT1 and MCT1 correlate with tumor grade and survival in clear-cell renal cell carcinoma. PLoS ONE 2018, 13, e0193477.
  17. Varia, M.A.; Calkins-Adams, D.P.; Rinker, L.H.; Kennedy, A.S.; Novotny, D.B.; Fowler, W.C.; Raleigh, J.A. Pimonidazole: A Novel Hypoxia Marker for Complementary Study of Tumor Hypoxia and Cell Proliferation in Cervical Carcinoma. Gynecol. Oncol. 1998, 71, 270–277.
  18. Danhier, P.; Krishnamachary, B.; Bharti, S.; Kakkad, S.; Mironchik, Y.; Bhujwalla, Z.M. Combining Optical Reporter Proteins with Different Half-lives to Detect Temporal Evolution of Hypoxia and Reoxygenation in Tumors. Neoplasia 2015, 17, 871–881.
  19. Godet, I.; Shin, Y.J.; Ju, J.A.; Ye, I.C.; Wang, G.; Gilkes, D.M. Fate-mapping post-hypoxic tumor cells reveals a ROS-resistant phenotype that promotes metastasis. Nat. Commun. 2019, 10, 4862.
  20. Robinson, M.F.; Dupuis, N.P.; Kusumoto, T.; Liu, F.; Menon, K.; Teicher, B.A. Increased Tumor Oxygenation and Radiation Sensitivity in two Rat Tumors by A Hemoglobin-Based, Oxygen-Carrying Preparation. Artif. Cells Blood Substit. Biotechnol. 1995, 23, 431–438.
  21. Sun, C.-J.; Li, C.; Lv, H.-B.; Zhao, C.; Yu, J.-M.; Wang, G.-H.; Luo, Y.-X.; Li, Y.; Xiao, M.; Yin, J.; et al. Comparing CT perfusion with oxygen partial pressure in a rabbit VX2 soft-tissue tumor model. J. Radiat. Res. 2014, 55, 183–190.
  22. Doss, M.; Zhang, J.J.; Bélanger, M.-J.; Stubbs, J.B.; Hostetler, E.D.; Alpaugh, K.; Kolb, H.C.; Yu, J.Q. Biodistribution and radiation dosimetry of the hypoxia marker 18F–HX4 in monkeys and humans determined by using whole-body PET/CT. Nucl. Med. Commun. 2010, 31, 1016–1024.
  23. Logothetis, N.K. The Underpinnings of the BOLD Functional Magnetic Resonance Imaging Signal. J. Neurosci. 2003, 23, 3963–3971.
  24. Cheng, M.H.Y.; Mo, Y.; Zheng, G. Nano versus Molecular: Optical Imaging Approaches to Detect and Monitor Tumor Hypoxia. Adv. Health Mater. 2021, 10, e2001549.
  25. Rickard, A.G.; Palmer, G.M.; Dewhirst, M.W. Clinical and Pre-clinical Methods for Quantifying Tumor Hypoxia. In Hypoxia and Cancer Metastasis; Springer: Berlin/Heidelberg, Germany, 2019; Volume 1136, pp. 19–41.
  26. Ohnishi, K.; Tani, T.; Bando, S.-I.; Kubota, N.; Fujii, Y.; Hatano, O.; Harada, H. Plastic induction of CD133AC133-positive cells in the microenvironment of glioblastoma spheroids. Int. J. Oncol. 2014, 45, 581–586.
  27. Seelam, S.R.; Hong, M.K.; Lee, Y.-S.; Jeong, J.M. Comparative study of 2-nitroimidazole-fluorophore-conjugated derivatives with pimonidazole for imaging tumor hypoxia. J. Radiopharm. Mol. Probes 2019, 5, 101–112.
  28. Hettie, K.S.; Klockow, J.L.; Moon, E.J.; Giaccia, A.J.; Chin, F.T. A NIR fluorescent smart probe for imaging tumor hypoxia. Cancer Rep. 2021, 4, e1384.
  29. D’Alonzo, R.A.; Gill, S.; Rowshanfarzad, P.; Keam, S.; MacKinnon, K.M.; Cook, A.M.; Ebert, M.A. In vivo noninvasive preclinical tumor hypoxia imaging methods: A review. Int. J. Radiat. Biol. 2021, 97, 593–631.
  30. AlSawaftah, N.; Farooq, A.; Dhou, S.; Majdalawieh, A.F. Bioluminescence Imaging Applications in Cancer: A Comprehensive Review. IEEE Rev. Biomed. Eng. 2021, 14, 307–326.
  31. Cecic, I.; Chan, D.A.; Sutphin, P.D.; Ray, P.; Gambhir, S.S.; Giaccia, A.J.; Graves, E.E. Oxygen Sensitivity of Reporter Genes: Implications for Preclinical Imaging of Tumor Hypoxia. Mol. Imaging 2007, 6, 219–228.
  32. O’Connor, J.P.B.; Robinson, S.P.; Waterton, J.C. Imaging tumour hypoxia with oxygen-enhanced MRI and BOLD MRI. Br. J. Radiol. 2019, 92, 20180642.
  33. Torres, J.P.; López-Larrubia, P.; Ballesteros, P.; Cerdán, S. Imaging tumor hypoxia by magnetic resonance methods. NMR Biomed. 2010, 24, 1–16.
  34. Krishna, M.C.; Matsumoto, S.; Yasui, H.; Saito, K.; Devasahayam, N.; Subramanian, S.; Mitchell, J.B. Electron Paramagnetic Resonance Imaging of Tumor pO2. Radiat. Res. 2012, 177, 376–386.
  35. Stieb, S.; Eleftheriou, A.; Warnock, G.; Guckenberger, M.; Riesterer, O. Longitudinal PET imaging of tumor hypoxia during the course of radiotherapy. Eur. J. Pediatr. 2018, 45, 2201–2217.
  36. Lee, C.-T.; Boss, M.-K.; Dewhirst, M.W. Imaging Tumor Hypoxia to Advance Radiation Oncology. Antioxid. Redox Signal. 2014, 21, 313–337.
  37. Springett, R.; Swartz, H.M. Measurements of Oxygen In Vivo: Overview and Perspectives on Methods to Measure Oxygen Within Cells and Tissues. Antioxid. Redox Signal. 2007, 9, 1295–1302.
  38. Daponte, A.; Ioannou, M.; Mylonis, I.; Simos, G.; Minas, M.; E Messinis, I.; Koukoulis, G. Prognostic significance of Hypoxia-Inducible Factor 1 alpha(HIF-1alpha) expression in serous ovarian cancer: An immunohistochemical study. BMC Cancer 2008, 8, 335.
  39. Ilie, M.; Mazure, N.M.; Hofman, V.; Ammadi, E.R.; Ortholan, C.; Bonnetaud, C.; Havet, K.; Venissac, N.; Mograbi, B.; Mouroux, J.; et al. High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer. Br. J. Cancer 2010, 102, 1627–1635.
  40. Nordsmark, M.; Loncaster, J.; Aquino-Parsons, C.; Chou, S.-C.; Gebski, V.; West, C.; Lindegaard, J.C.; Havsteen, H.; Davidson, S.E.; Hunter, R.; et al. The prognostic value of pimonidazole and tumour pO2 in human cervix carcinomas after radiation therapy: A prospective international multi-center study. Radiother. Oncol. 2006, 80, 123–131.
  41. Dunwoodie, S.L. The Role of Hypoxia in Development of the Mammalian Embryo. Dev. Cell 2009, 17, 755–773.
  42. Chen, P.-S.; Chiu, W.-T.; Hsu, P.-L.; Lin, S.-C.; Peng, I.-C.; Wang, C.-Y.; Tsai, S.-J. Pathophysiological implications of hypoxia in human diseases. J. Biomed. Sci. 2020, 27, 63.
  43. Digiacomo, J.W.; Gilkes, D.M. Tumor Hypoxia as an Enhancer of Inflammation-Mediated Metastasis: Emerging Therapeutic Strategies. Target. Oncol. 2018, 13, 157–173.
  44. Digiacomo, J.W.; Gilkes, D.M. Therapeutic Strategies to Block the Hypoxic Response. In Hypoxia and Cancer Metastasis; Springer: Berlin/Heidelberg, Germany, 2019; Volume 1136, pp. 141–157.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Cell Biology; Oncology
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Ines Godet
View Times: 333
Revisions: 2 times (View History)
Update Date: 01 Mar 2022
Table of Contents
    1000/1000
    Hot Most Recent
    Video Production Service
    Feedback